Palisade Bio(NASDAQ) PALI

Palisade Bio, Inc. creates oral drugs for inflammatory bowel diseases. These medicines help patients manage chronic conditions like ulcerative colitis. The company focuses on delivering treatments directly to the gut.

Fighting Gut Disease

• PALI-2108: Oral prodrug designed to treat inflammatory bowel disease by targeting the lower intestine.
• LB1148: Liquid formulation intended to protect gut integrity during surgery or infection.
• Precision Medicine: Biomarker-based selection approach used to identify patients likely to respond to therapy.

Key Steps Forward

• Completed the Phase 1 clinical program for PALI-2108 during the first half of 2026.
• Received FDA clearance for a Phase 2 clinical trial in June 2026.
• Announced positive results for its Crohn's disease study on March 30, 2026.
• Completed an underwritten offering in October 2025 that raised $127.6 million in net proceeds.

Why Their Science Differs

Palisade uses local bacterial bioactivation to deliver medicine directly to the colon while minimizing side effects. Its precision medicine approach uses biomarkers to identify specific patients who are most likely to benefit from its therapies.

Cash and Operating Results

• Cash and cash equivalents reached $125.2 million as of June 30, 2026.
• Research and development expenses were $7.4 million for the three months ended June 30, 2026, up 342% year over year.
• Net loss was $10.6 million for the three months ended June 30, 2026, up 280% year over year.
• License revenue totaled $500,000 for the six months ended June 30, 2026, earned from a milestone achievement.

Evolution of the Business

Palisade has transitioned from early clinical evaluation to mid-stage development for its lead inflammatory bowel disease candidate. The company maintains a significant cash position to fund its primary efficacy trials through 2027 and 2028.